The Cardio-renal Syndrome (CRS)

Scabbia, E; Scabbia, Luca

doi:10.1016/j.ijcme.2014.10.013

Cited by 6 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This well-described phenomenon of a paired decline in renal and cardiac function is termed the cardiorenal syndrome [5]. As such, the patients in our cohort who suffered CA-AKI and later developed HF may be classified by this syndrome, specifically type 3 or type 4, in which acute decline (type 3) or chronic abnormalities (type 4) of renal function cause cardiac dysfunction [26]. …”

Section: Discussionmentioning

confidence: 99%

Community-Acquired Acute Kidney Injury as a Risk Factor of de novo Heart Failure Hospitalization

Tecson¹,

Hashemi²,

Afzal³

et al. 2019

Cardiorenal Med

View full text Add to dashboard Cite

Objectives: Because patients with hospital-acquired acute kidney injury (AKI) are at risk for subsequent development of heart failure (HF) and little is known about the relation between community-acquired AKI (CA-AKI) and HF, we sought to determine if CA-AKI is a risk factor for incident HF hospitalization. Methods: We utilized Baylor Scott & White Health databases at the primary care and inpatient hospitalization levels to identify adults without a prior history of HF who had 2 or more serum creatinine measurements within 13 months in the primary care setting. We defined CA-AKI as a serum creatinine increase ≥0.3 mg/dL or ≥1.5 times the baseline for consecutive values within a 13-month period. We created a flag for de novo HF hospitalization at 90, 180, and 365 days following CA-AKI evaluation. Results: In the analyses, 210,895 unique adults were included, of whom 5,358 (2.5%) had CA-AKI. Those with CA-AKI had higher rates of comorbidities, higher rate of males (48 vs. 42%, p < 0.001), and were older (61.5 [50.3, 73.1] vs. 54.1 [42.8, 64.7] years, p < 0.001) than those who did not have CA-AKI. In total, 607 (0.3%), 833 (0.4%), and 1,089 (0.5%) individuals had an incident HF hospitalization in the 90, 180, and 365 days following the CA-AKI evaluation, respectively. After adjusting for demographic and clinical characteristics, patients with CA-AKI had >2 times the risk of de novo HF hospitalization compared with patients who did not have CA-AKI (90 days: 2.35 [1.83–3.02], p < 0.001; 180 days: 2.52 [2.04–3.13], p < 0.001; 365 days: 2.16 [1.77–2.64], p < 0.001). These multivariable models yielded strong predictive abilities, with the areas under the receiver-operating characteristic curve >0.90. Conclusion: After controlling for baseline and clinical characteristics, patients with CA-AKI were at approximately twofold the risk of de novo HF hospitalization (within 90, 180, and 365 days) compared with those who did not have CA-AKI. Hence, detecting CA-AKI may provide an opportunity for early intervention at the primary care level to possibly delay HF development.

show abstract

Section: Discussionmentioning

confidence: 99%

Community-Acquired Acute Kidney Injury as a Risk Factor of de novo Heart Failure Hospitalization

Tecson¹,

Hashemi²,

Afzal³

et al. 2019

Cardiorenal Med

View full text Add to dashboard Cite

show abstract

“…Severe renal function impairment, as indicated by an increment of baseline serum creatinine above 0.3 mg/dl, takes place in variable proportions in 27% to 40% of individuals with severe coronary syndrome and acute heart failure [5]. Studies have indicated that cardiorenal syndrome type 1 development may lead to considerable deterioration with regard to prolonged hospital admission, mortality, and morbidity [12][13][14][15].…”

Section: Crs Type I (Acute Cardiorenal Syndrome)mentioning

confidence: 99%

“…Due to the common concomitance of severe kidney disease and chronic cardiac impairment, it is difficult to determine which conditions are pre-existing; thus, an accurate anamnestic reconstruction is paramount. Furthermore, the concomitance of the renal and cardiac conditions tends to worsen the prognosis in relation to the increased risk of morbidity and mortality [4,[13][14][15]. Therefore, it may be concluded that renal failure is one of the negative prognostic factors with regard to the independent evaluation of the heart failure framework's evolution.…”

Section: Crs Type II (Chronic Cardiorenal Syndrome)mentioning

confidence: 99%

Cardiorenal Syndrome: A Literature Review

Ajibowo,

Okobi,

Emore

et al. 2023

Cureus

View full text Add to dashboard Cite

Cardiorenal syndrome (CRS) is a condition characterized by the intricate two-way relationship between the heart and kidneys, which can lead to acute or chronic dysfunction in these organs. The interplay between cardiorenal connectors and both hemodynamic and non-hemodynamic factors is crucial to understanding this syndrome. The clinical importance of these interactions is evident in the changes observed in hemodynamic factors, neurohormonal markers, and inflammatory processes. Identifying and understanding biomarkers associated with CRS is valuable for early detection and enabling intervention before significant organ dysfunction occurs. This comprehensive review focuses on the clinical significance of biomarkers in the diagnosis, prognosis, and management of CRS. Finally, it highlights the necessity for further advancements in managing this condition.

show abstract

“…The role of aldosterone in CHF development including myocardial injury is beyond argument [7]. As a component of angiotensin aldosterone system, it significantly influences fluid retention and edema formation, potassium excretion and sodium retention, remodeling, fibroid heart and vessels sclerosis.…”

Section: Problem Statement and Analysis Of The Recent Researchmentioning

confidence: 99%

Dynamics of Heart Failure Markers in Patients after Past Myocardial Infarction with the Use of Potassium and Magnesium Salts of Gluconic Acid, Eplerenone and Rivaroxaban

Савчук

Vakaliuk

2017

Arch. clin. med.

View full text Add to dashboard Cite

The objective of the research was to increase the efficiency of treatment of patients with chronic heart failure (CHF) and post-infarction cardiosclerosis by adding potassium and magnesium salts of gluconic acid, eplerenone and rivaroxaban to the background therapy taking into account the indices of growth differentiation factor 15 (GDF-15), aldosterone and galectin-3. Materials and methods of the research. Emmunoenzymometric determination of the galectin-3, GDF-15 and aldosterone levels concentration in blood serum was conducted to achieve the stated objective. 42 patients with CHF and post-infarction cardiosclerosis after coronary artery stenting in the acute period of myocardial infarction (MI) were examined. The patients were randomized into four groups according to the peculiarities of treatment. Group I included patients with CHF and post-infarction cardiosclerosis treated with the background therapy (BT). Group II consisted of patients with CHF who were treated with BT and addition of potassium and magnesium salts of gluconic acid. Group III included patients with CHF who were prescribed eplerenone secondary to BT. Group IV consisted of patients who were treated with BT and rivaroxaban. Results. The proposed treatment regimens were proved to be effective in reduction of GDF-15, aldosterone and galectin-3 indices in 12 months of treatment. Conducted therapy with the use of rivaroxaban secondary to BT led to more intensive decrease in GDF-15 concentration in comparison with the use of potassium and magnesium salts of gluconic acid or eplerenone on the background of BT. This index constituted (2110.21±107.4) pg/ml before the treatment in these patients and significantly decreased to (1286.75±109.6) pg/ml being significantly before the therapy. The performed treatment with the use of eplerenone secondary to BT was proved to be more effective for normalization of aldosterone and galectin-3 levels in blood serum compared to other studied treatment regimens. The average value of aldosterone changed in the treatment process by 67.24%. Thus, the average level of this index constituted (139.8±7.63) pg/ml before the treatment and was equal to (45.8±5.52) pg/ml at the end of the treatment course. The average value of galectin-3 in patients with CHF and post-infarction cardiosclerosis was noted to be (34.69±1.67) ng/ml before the treatment. It constituted (22.53±0.98) ng/ml after the end of treatment being significantly lower compared to the value before the treatment. The average value of this index changed in the course of twelve-month treatment by 35.05%. Lower risk of sudden cardiac arrest (SCA), acute coronary syndrome (ACS) and stroke was observed in the patients with CHF and post-infarction cardiosclerosis with the use of rivaroxaban secondary to BT. Conclusions. Thus, the use of rivaroxaban combination therapy secondary to BT led to more intensive decrease in GDF-15 concentration in comparison with the use of potassium and magnesium salts of gluconic acid or eplerenone. Conducted therapy with the use o...

show abstract

The Cardio-renal Syndrome (CRS)

Cited by 6 publications

References 30 publications

Community-Acquired Acute Kidney Injury as a Risk Factor of de novo Heart Failure Hospitalization

Community-Acquired Acute Kidney Injury as a Risk Factor of de novo Heart Failure Hospitalization

Cardiorenal Syndrome: A Literature Review

Dynamics of Heart Failure Markers in Patients after Past Myocardial Infarction with the Use of Potassium and Magnesium Salts of Gluconic Acid, Eplerenone and Rivaroxaban

Contact Info

Product

Resources

About